


I hereby certify that this paper is being deposited with the U.S. Postal Service as
Express Mail, Airbill No. EV 881238510 US, on the date shown below in an
envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450.

Dated: May 22, 2007

Signature: 
(Grace L. Liu)

Patent
Docket No. 511582003500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mary FARIS et al.

Serial No.: 09/809,638

Filing Date: March 14, 2001

For: 125P5C8: A TISSUE SPECIFIC
PROTEIN HIGHLY EXPRESSED IN
VARIOUS CANCERS

Examiner: A. Harris

Group Art Unit: 1643

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **511582003500**.

Dated: May 22, 2007

Respectfully submitted,

By 
James J. Mullen III, Ph.D.
Registration No.: 44,957
MORRISON & FOERSTER LLP
12531 High Bluff Drive, Suite 100
San Diego, California 92130-2040
(858) 720-7940



ALTERNATIVE TO PTO/SB/08A/B (04/07)

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	09/809,638
				Filing Date	March 14, 2001
				First Named Inventor	Mary FARIS
				Art Unit	1643
				Examiner Name	A. Harris
Sheet	1	of	2	Attorney Docket Number	511582003500

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
1.	GB-2,211,504		07/1989		
2.	WO-01/75067		10/2001		
3.	WO-01/94629		12/2001		
4.	WO-02/10449		02/2002		
5.	WO-02/26982		04/2002		
6.	WO-02/55700		07/2002		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
7.	ABDEL-MALEK, J. Cell Physiol. (1988) 136:247				
8.	ABE and SAITO, J. Neurochem. (2001) 76:217-223				
9.	BATRA et al., Prostate. (1991) 19:299				
10.	CHEN, Current Opinion in Immunology (1999) 11(2):219-222				
11.	CRAFT et al., Cancer Res. (1999) 59:5030-5036				
12.	DATABASE UNIPROT, Accession No. Q9H720 (March 2001)				
13.	DAVIES et al., Science (2000) 290:2295				
14.	FILETTI et al., Eur. J. Endocrinol. (1999) 141:443				
15.	FU et al., Int. J. Cancer (1992) 52(6):987-990				
16.	GERGELY et al., Clin. Diagn. Lab. Manual (1997) 4:70				
17.	HOLLO et al., Biochimica et Biophysica Acta (1994) 1191:384				
18.	HUBERT et al., Proc. Natl. Acad. Sci. USA (1999) 96(25):14523-14528				
19.	IVANOV and RONAI, Oncogene (2000) 19:3003				
20.	JANULIS et al., J. Biol. Chem. (1999) 274:801				
21.	KRUEGER et al., Cancer Res. (1999) 59:6010				
22.	KAIGHN et al., Invest. Urol. (1979) 17(1):16-23				
23.	KLEIN et al., Nature Med. (1997) 3:402-408				
24.	KUBOTA, J. Cell Biochem. (1994) 56(1):4-8				
25.	LEITH et al., Blood (1995) 86:2329				
26.	LINSLEY et al., J. Exp. Med. (1991) 174:561-566				
27.	MIRZA et al. Cell Growth Differ. (2000) 11:279				

Examiner Signature	Date Considered
--------------------	-----------------

sd-374732



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	511582003500
-------	---	----	---	------------------------	--------------

28.	MORTON and MYSZKA, Methods in Enzymology (1998) 295:268	
29.	MUSIL et al., J. Biol. Chem. (2000) 275:25207	
30.	PEMBERTON et al., J. of Histochemistry and Cytochemistry (1997) 45:1697-1706	
31.	SAFFRAN et al., PNAS (2001) 98(5):2658-2663	
32.	SKRYMA et al., J. Physiol. (2000) 527:71	
33.	SPITZWEG et al., Cancer Res. (2000) 60:6526	
34.	STORRIE et al., Methods Enzymol. (1990) 182:203-225	
35.	SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT for EP 02726630.3, Mailed on 10 January 2007, 4 pages	
36.	TAZEBAY et al., Nat. Med. (2000) 6:871	
37.	WELFORD, OPT. QUANT. ELECT. (1991) 23:1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

sd-374732